A detailed history of Bayesian Capital Management, LP transactions in Altimmune, Inc. stock. As of the latest transaction made, Bayesian Capital Management, LP holds 14,700 shares of ALT stock, worth $93,639. This represents 0.01% of its overall portfolio holdings.

Number of Shares
14,700
Holding current value
$93,639
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$6.02 - $9.85 $88,494 - $144,795
14,700 New
14,700 $105,000
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $5,175 - $8,955
1,500 Added 5.23%
30,175 $106,000
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $120,148 - $482,600
28,675 New
28,675 $121,000
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $271,114 - $569,415
25,409 New
25,409 $324,000
Q2 2022

Aug 15, 2022

SELL
$3.94 - $11.77 $66,192 - $197,736
-16,800 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $99,120 - $158,760
16,800 New
16,800 $102,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $312M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.